Long-term Study of DSP-5423P in Patients with Schizophrenia

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080222713

Enrollment

200

Registered

2015-01-07

Start date

2015-02-24

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Schizophrenia

Interventions

investigational material(s) Generic name etc : DSP-5423P INN of investigational material : Blonanserin Therapeutic category code : 1-- Agents affecting nervous system and sensory organs Dosage and Adm

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients who have schizophrenia diagnosed by DSM-5, diagnostic criteria Patients who are aged 18 years or older at informed consent Patient understands the objectives and procedures of the study and who provide written voluntarily consent to participate in the study, etc.

Exclusion criteria

Exclusion criteria: Patients who fall under a contraindication listed in the LONASEN package insert Patients with Parkinson disease, etc.

Design outcomes

Primary

Measure	Time frame
safety Adverse events (AEs) and adverse drug reaction (ADRs) Extrapyramidal AEs and ADRs Skin-related AEs and ADRs at the application site, etc	—

Secondary

Measure	Time frame
efficacy Change in PANSS total score from DSP-5423P baseline, etc.	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026